>

Zealand Pharma Fundamental Trends Analysis

<div class='circular--portrait' style='background:#0D8ECF;color: white;font-size:3em;padding-top: 40px;;'>ZEA</div>
ZEAL -- Denmark Stock  

DKK 224.20  11.80  5.56%

The Drivers Module shows relationships between Zealand Pharma's most relevant fundamental drivers and provides multiple suggestions of what could possibly affect the performance of Zealand Pharma AS over time as well as its relative position and ranking within its peers. Check out Your Current Watchlist
View Current Fundamental Trends For
Refresh
Sales per Share is projected to rize to 1.46 this yearZealand Pharma Operating Income is quite stable at the moment as compared to the last year. The company current value of Operating Income is estimated at about 633.51 Million. Net Income Per Employee is projected to rize to about 3.8 M this year, although the value of Net Loss will most likelly fall to (508.2 M).

Zealand Pharma AS Price to Book vs. Current Valuation Fundamental Analysis

Zealand Pharma AS is rated second in current valuation category among related companies. It is rated second in price to book category among related companies . The ratio of Current Valuation to Price to Book for Zealand Pharma AS is about  983,050,847 
Zealand Pharma AS is rated second in current valuation category among related companies. After adjusting for long-term liabilities, total market size of Biotechnology industry is at this time estimated at about 12.76 Billion. Zealand Pharma totals roughly 6.38 Billion in current valuation claiming about 50% of stocks in Biotechnology industry.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Zealand Pharma 
Enterprise Value 
 = 
Market Cap + Debt 
-  
Cash 
=
6.38 B
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Zealand Pharma 
P/B 
 = 
MV Per Share 
BV Per Share 
=
6.49 
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.

Zealand Price to Book Comparison

Zealand Fundamental Comparison

Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page